New York Life Investment Management LLC Has $6 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

New York Life Investment Management LLC decreased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 8.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,923 shares of the medical research company’s stock after selling 2,450 shares during the quarter. New York Life Investment Management LLC’s holdings in IQVIA were worth $5,998,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in IQV. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the fourth quarter worth about $13,759,000. Schwartz Investment Counsel Inc. increased its holdings in shares of IQVIA by 4.1% in the fourth quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock worth $41,345,000 after acquiring an additional 7,050 shares in the last quarter. Gilliland Jeter Wealth Management LLC bought a new stake in shares of IQVIA in the fourth quarter worth about $986,000. Dfpg Investments LLC bought a new stake in shares of IQVIA in the fourth quarter worth about $1,106,000. Finally, Sei Investments Co. increased its holdings in shares of IQVIA by 20.2% in the third quarter. Sei Investments Co. now owns 94,748 shares of the medical research company’s stock worth $18,641,000 after acquiring an additional 15,913 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Buying and Selling

In related news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now directly owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,285 shares of company stock valued at $10,331,003. Insiders own 1.60% of the company’s stock.

IQVIA Stock Up 0.6 %

IQV stock opened at $223.39 on Friday. The company has a quick ratio of 0.86, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The business has a 50 day moving average price of $244.56 and a two-hundred day moving average price of $223.84. The company has a market cap of $40.55 billion, a price-to-earnings ratio of 30.52, a P/E/G ratio of 2.15 and a beta of 1.52. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The firm had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. During the same period last year, the company earned $2.54 earnings per share. The business’s revenue was up 3.5% compared to the same quarter last year. Analysts anticipate that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of several recent analyst reports. Evercore ISI lowered their price target on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a report on Friday. BTIG Research began coverage on IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price target for the company. Robert W. Baird decreased their price objective on IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a report on Friday. Guggenheim downgraded IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Finally, SVB Leerink began coverage on IQVIA in a report on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective for the company. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $257.57.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.